Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
暂无分享,去创建一个
[1] Gianfranco Parati,et al. Assessment and management of blood-pressure variability , 2013, Nature Reviews Cardiology.
[2] J. Blacher,et al. Effect of Antihypertensive Agents on Blood Pressure Variability: The Natrilix SR Versus Candesartan and Amlodipine in the Reduction of Systolic Blood Pressure in Hypertensive Patients (X-CELLENT) Study , 2011, Hypertension.
[3] K. Reynolds,et al. The Relationship Between Visit-to-Visit Variability in Systolic Blood Pressure and All-Cause Mortality in the General Population: Findings From NHANES III, 1988 to 1994 , 2011, Hypertension.
[4] Eoin O'Brien,et al. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke , 2010, The Lancet Neurology.
[5] Jordan Muraskin,et al. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. , 2010, Archives of neurology.
[6] P. Rothwell,et al. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension , 2010, The Lancet.
[7] Yutaka Imai,et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring , 2008, Journal of hypertension.
[8] A. Dominiczak,et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.
[9] A. Dominiczak,et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.
[10] Piotr Ponikowski,et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, European heart journal.
[11] R. Collins,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri , 2005, The Lancet.
[12] Yutaka Imai,et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. , 2005, Journal of hypertension.
[13] Daniel W. Jones,et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. , 2005, Hypertension.
[14] P. Libby,et al. Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure The CAMELOT Study: A Randomized Controlled Trial , 2004 .
[15] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[16] John M Flack,et al. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. , 2003 .
[17] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[18] S. Kes,et al. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine , 2003, Current medical research and opinion.
[19] B. Davis,et al. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.
[20] Anne Whitehead,et al. Meta-Analysis of Controlled Clinical Trials , 2002 .
[21] S L Normand,et al. Meta-analysis: formulating, evaluating, combining, and reporting. , 1999, Statistics in medicine.
[22] G Parati,et al. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. , 1987, Journal of hypertension.
[23] Qi-gui Yu,et al. [Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients]. , 2012, Zhonghua xin xue guan bing za zhi.